Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 6/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21459657 | 0.93 | POLQ (0.33) | POLQTACR1PSEN1PSEN2APH1B | |
| SCHEMBL23255967 | 0.91 | — | — | |
| SCHEMBL29610810 | 0.90 | F11 (0.31) | POLQCCR2 | |
| SCHEMBL31629607 | 0.89 | F11 (0.31) | ACKR3 | |
| SCHEMBL23257239 | 0.89 | F11 (0.33) | ACKR3CCR2 | |
| SCHEMBL23256691 | 0.89 | ACKR3 (0.32) | ACKR3 | |
| SCHEMBL23250487 | 0.89 | THRA (0.31) | ACKR3 | |
| SCHEMBL23250390 | 0.87 | POLQ (0.34) | POLQTACR1CCR2 | |
| SCHEMBL24307588 | 0.86 | GCG (0.34) | CCR2 | |
| SCHEMBL29611527 | 0.86 | GCG (0.34) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | MORPHIC THERAPEUTIC, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-116783161-A | Inhibition of human integrin A4B7 | 莫菲克医疗股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4228634-A1 | INHIBITING HUMAN INTEGRIN A4B7 | Morphic Therapeutic, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-115087444-A | Inhibition of human integrin alpha 4 β 7 | 莫菲克医疗股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4045039-A1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022081983-A1 | INHIBITING HUMAN INTEGRIN A4B7 | MORPHIC THERAPEUTIC, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081983-A1 | INHIBITING HUMAN INTEGRIN A4B7 | MORPHIC THERAPEUTIC, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021076890-A1 | INHIBITING HUMAN INTEGRIN α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076890-A1 | INHIBITING HUMAN INTEGRIN α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | ITGB7, ITGB4, ITGA4 | POLQ 4266/4885TACR1 2883/4885PSEN1 2392/4885 |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | ITGB7, ITGB4, ITGA4 | POLQ 4266/4885TACR1 2883/4885PSEN1 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.